Search...
Kymera rises on upcoming data release for eczema asset KT-621
Kymera Therapeutics' stock rose ~9% after announcing the release of phase 1b data for its eczema candidate KT-621 on Dec. 8. KT-621 is an oral STAT6 degrader, targeting Th2 inflammation in allergic diseases. The release will include a press release and webcast. Potential indications include asthma and COPD.
Source: businessinsider The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments